
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) – Analysts at HC Wainwright lifted their Q4 2026 EPS estimates for Relmada Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.09) per share for the quarter, up from their prior estimate of ($0.14). The consensus estimate for Relmada Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Relmada Therapeutics’ Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.45) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at $0.01 EPS.
Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02.
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.
Relmada Therapeutics Stock Down 14.3%
Shares of NASDAQ:RLMD opened at $3.61 on Tuesday. Relmada Therapeutics has a 12 month low of $3.07 and a 12 month high of $8.00. The company’s fifty day simple moving average is $3.75 and its 200 day simple moving average is $5.33. The firm has a market cap of $385.08 million, a price-to-earnings ratio of -5.01 and a beta of 0.62.
Insider Activity
In other news, CFO Maged Shenouda bought 120,200 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were acquired at an average price of $4.20 per share, with a total value of $504,840.00. Following the transaction, the chief financial officer owned 920,200 shares in the company, valued at $3,864,840. This represents a 15.02% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.50% of the company’s stock.
Hedge Funds Weigh In On Relmada Therapeutics
A number of large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in shares of Relmada Therapeutics by 14.8% in the third quarter. Goldman Sachs Group Inc. now owns 880,889 shares of the company’s stock valued at $3,321,000 after purchasing an additional 113,265 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Relmada Therapeutics by 2,093.3% in the third quarter. Russell Investments Group Ltd. now owns 165,861 shares of the company’s stock worth $625,000 after purchasing an additional 158,299 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Relmada Therapeutics by 31.8% during the third quarter. Alps Advisors Inc. now owns 140,319 shares of the company’s stock worth $529,000 after purchasing an additional 33,863 shares during the last quarter. Profund Advisors LLC boosted its holdings in Relmada Therapeutics by 615.6% during the third quarter. Profund Advisors LLC now owns 195,555 shares of the company’s stock worth $737,000 after purchasing an additional 168,229 shares during the last quarter. Finally, AXQ Capital LP acquired a new position in Relmada Therapeutics during the second quarter worth $84,000. Institutional investors and hedge funds own 45.24% of the company’s stock.
Key Relmada Therapeutics News
Investors following RLMD have been watching these news items:
- Positive Sentiment: HC Wainwright raised its EPS forecasts across several periods, including FY2027 to a loss of $0.52 per share from $0.61, FY2028 to a loss of $0.45 from $0.52, and FY2030 to a profit of $0.01 from a loss of $0.06. It also reduced projected losses for quarters from Q4 2026 through Q4 2027. The revisions suggest the analyst expects a narrower path of losses, though RLMD is still forecast to remain unprofitable for several years. MarketBeat Relmada Therapeutics
- Positive Sentiment: Relmada appointed Dr. Jørn Skibsted Jakobsen as Chief Development Officer for Urology & Uro-Oncology. His experience leading the development program for an approved bladder-cancer therapy may strengthen execution as Relmada prepares the Phase 3 SPECTRUM program for NDV-01. The company cited encouraging Phase 2 results, but Phase 3 has not yet established the candidate’s efficacy or safety. Relmada appointment announcement
About Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing investigational treatments for central nervous system disorders, with a focus on depression. The company’s work centers on advancing drug candidates through clinical research; it does not have an approved commercial product. Its best-known candidate, REL-1017 (esmethadone), is an oral compound that acts on NMDA receptors. Relmada has studied it as an add-on treatment for adults with major depressive disorder who have not responded adequately to existing antidepressants.
See Also
- Five stocks we like better than Relmada Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
